Get Even More Visitors To Your Blog, Upgrade To A Business Listing >>
Idioma: En

Is the FDA a Big Risk to This Company’s Marijuana Plans?

http://ift.tt/2rd29z1

Insys Therapeutics NASDAQ INSY 160 might have a problem on its hands This week the FDA requested that Endo International NASDAQ ENDP remove its opioid medication Opana ER from the market and that news raises the question Who s next If Insys Therapeutics

Related Articles

June 11, 2017 at 12:01PM

http://ift.tt/2t8DvMd

from

http://ift.tt/2t8DvMd




This post first appeared on Corporate Governance, please read the originial post: here

Share the post

Is the FDA a Big Risk to This Company’s Marijuana Plans?

×

Subscribe to Corporate Governance

Get updates delivered right to your inbox!

Thank you for your subscription

×